Article Sidebar
Article Details
Issue
Section
Articles
Main Article Content
Prevalence and Pattern of Renal Bone Disease in End Stage Renal Disease Patients in Ile-Ife, Nigeria
Abstract
BACKGROUND: Information on renal bone disease (RBD) is
sparse in Nigeria. The prevalence of RBD in a dialysis population worldwide ranges between 33% and 67% and it increases with progression of renal insufficiency.
OBJECTIVE: To determine the prevalence and magnitude of
RBD in patients with end stage renal disease (ESRD).
METHODS: Thirty consecutive ESRD patients were recruited. They had thorough clinical evaluation and investigations which included serum calcium, phosphate, alkaline phosphatase, albumin and skeletal survey. The serum iPTH, osteocalcin, and 1,25 (OH2) D3 were assessed in 20 patients.
RESULTS: The patients were aged 18–72 years with a mean of 38.93±15.7 years. There was a male:female ratio of 4:1. Uraemic symptoms were the major presenting complaints. None of the patients complained of bone pain or fracture. The mean values for serum creatinine, urea, creatinine clearance, calcium, phosphate, albumin, alkaline phosphatase, iPTH,
osteocalcin and 1,25 (OH)2 Vit D3 were 1478.96 ± 771.12 ìmol/L, 22.33 ± 7.42 mmol/L, 3.38 ± 2.22 mls/min, 1.8 ± 0.5mmol/L, 1.61 ± 0.65 mmol/L, 30.2 ± 6.1 g/L, 124.33 ± 63.37 IU/L, 22.66 ± 24.72, 45.14 ± 43.8, 37.7 ± 22.3 respectively. There were hypocalcaemia and hyperphosphataemia in 80% and 60% of the patients respectively.
Alkaline phosphatase was elevated in 44% of the patients while 11.8% had hyperparathyroidism. Level of 1,25 (OH)2 Vit D3 was low in 83.3% of the patients. There was a significant negative correlation between serum calcium and iPTH levels (r = –0.915, p=0.029). There was also significant negative correlation between alkaline phosphatase and 1,25 (OH)2 Vit
D3 and serum albumin. Radiological evidence of RBD occurred in only 16.7% of the patients.
CONCLUSION: Renal bone disease is common in our patients with ESRD associated most commonly with low bone turnover while occurrence of hyperparathyroid bone disease appears low
sparse in Nigeria. The prevalence of RBD in a dialysis population worldwide ranges between 33% and 67% and it increases with progression of renal insufficiency.
OBJECTIVE: To determine the prevalence and magnitude of
RBD in patients with end stage renal disease (ESRD).
METHODS: Thirty consecutive ESRD patients were recruited. They had thorough clinical evaluation and investigations which included serum calcium, phosphate, alkaline phosphatase, albumin and skeletal survey. The serum iPTH, osteocalcin, and 1,25 (OH2) D3 were assessed in 20 patients.
RESULTS: The patients were aged 18–72 years with a mean of 38.93±15.7 years. There was a male:female ratio of 4:1. Uraemic symptoms were the major presenting complaints. None of the patients complained of bone pain or fracture. The mean values for serum creatinine, urea, creatinine clearance, calcium, phosphate, albumin, alkaline phosphatase, iPTH,
osteocalcin and 1,25 (OH)2 Vit D3 were 1478.96 ± 771.12 ìmol/L, 22.33 ± 7.42 mmol/L, 3.38 ± 2.22 mls/min, 1.8 ± 0.5mmol/L, 1.61 ± 0.65 mmol/L, 30.2 ± 6.1 g/L, 124.33 ± 63.37 IU/L, 22.66 ± 24.72, 45.14 ± 43.8, 37.7 ± 22.3 respectively. There were hypocalcaemia and hyperphosphataemia in 80% and 60% of the patients respectively.
Alkaline phosphatase was elevated in 44% of the patients while 11.8% had hyperparathyroidism. Level of 1,25 (OH)2 Vit D3 was low in 83.3% of the patients. There was a significant negative correlation between serum calcium and iPTH levels (r = –0.915, p=0.029). There was also significant negative correlation between alkaline phosphatase and 1,25 (OH)2 Vit
D3 and serum albumin. Radiological evidence of RBD occurred in only 16.7% of the patients.
CONCLUSION: Renal bone disease is common in our patients with ESRD associated most commonly with low bone turnover while occurrence of hyperparathyroid bone disease appears low
